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Abstract
Background: Neoadjuvant chemotherapy (NC+) and portal vein embolization (PVE) enables curative
resection in more patients with colorectal-liver metastases (CRLM). However, after NC+, structural alter-
ations have been reported with the risk of post-operative hepatic failure. We undertook to determine if NC+
toxicity limits future remnant liver (FRL) hypertrophy after PVE.
Methods: PVE was performed in 20 patients, 13 (65%) of whom previously received a mean FOLFIRI
(5-fluorouracil + leucovorin + irinotecan) regimen (NC+) of 6.6 cycles. The seven remaining patients served
as the control group without NC (NC-).
Results: CRLM were bilateral in 69% (NC+) and 57% (NC-), and synchronous in 84% (NC+) and 14%
(NC-). The FRL hypertrophy rate was 54.1% (NC+) and 43.7% (NC-) (P = 0.3). CRLM were unresectable
in four of our 20 patients, i.e. group NC+: one insufficient FRL hypertrophy and one severe steatosis; and
group NC-: two tumoral progressions. In both groups, the operative parameters were comparable except
for pedicular clamping: 8 (NC+) and 36 min (NC-), respectively (P < 0.05). Also, the surgical outcome rate
and hospital stay were comparable. No significant pathological difference was observed between the two
groups. No mortality occurred in either group.
Conclusion: In view of our limited experience, we conclude that hypertrophy of the non-embolized liver
(FRL) is not altered after FOLFIRI-based NC.
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Introduction
Liver resection is the sole curative approach to colorectal-liver
metastases (CRLM) with a 5-year survival rate of about 50%,
especially when it is combined with chemotherapy. However,
only 10–15% of patients could be eligible for curative resec-
tion.1,2 The limiting factors are diffuse metastases and future
remnant liver (FRL) volume that may be reduced by CRLM dis-
tribution.3 Additionally, patients can undergo curative resection
with portal vein embolization (PVE) and systemic neoadjuvant
chemotherapy (NC).3–8 FRL increases after PVE and can be
amended to resection without post-hepatectomy dysfunction.3,7,9
NC reduces tumor size, controls micrometastatic disease and
makes chemotherapy a predictive factor of successful liver
resection.8,10 After chemotherapy, liver toxicity is well docu-
mented, with structural studies identifying hepatic alterations
such as veno-occlusive lesions as well as steatosis and a possible
worse post-operative course.11,12 NC and PVE have been used
complementarily, and usually NC is interrupted for 1 month
before PVE and consequently until surgery to avoid hepatic
regeneration defects13 with, however, the risk of tumoral
progression.14
To assess the impact of chemotherapy on hypertrophy of the
FRL after right portal vein embolization, we retrospectively
studied a group of 20 patients that underwent PVE to allow
CRLM resection. We compared FRL hypertrophy in 13 patients
receiving systemic NC (group NC+) and seven control patients
without NC (group NC-). FRL hypertrophy and the tumoral
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response with resulting conversion to resectability and post-
operative course were the main target points.
Patients and methods
From January 2004 to March 2006, 20 CRLM patients were admit-
ted for PVE preceding planned liver resection. Primary tumors
were found in the right (n = 4), transverse (n = 1) or left (n = 8)
colon and rectum (n = 7). Mean age was 60  2 years, and the
mean of metastases was three (range 1–8) which were bilobular in
13/20 (65%) and synchronous to primary in 12/20 (60%). There
were no extra-hepatic metastases. CRLM were judged to be pri-
marily unresectable because of their number and/or distribution
(two lobes). The NC- group underwent PVE for FRL <30% in
three patients, and for FRL <40% in four patients with severe fatty
liver or when a bilateral liver resection was planed. In the NC+
group, all patients underwent PVE because FRL was <40%.
Right PVE was performed by the contralateral transhepatic
left portal vein puncture under light neuroleptanalgesia and
ultrasound guidance. After portography, the right anterior and
posterior portal branches were embolized with cyanoacrylate
(Histoacryle; Braun Lab, Hamburg, Germany) and lipiodol (Lipi-
odol Ultrafluid; Guerbert Lab, Paris, France) in 18 patients and
with an Amplazer vascular plug (AGA Medical Corporation, Ply-
mouth, MN, USA) in two patients. PVE was extended to segment
IV in four patients (1 NC- and 3 NC+) when extended right
hepatectomy was planned. Surgery was scheduled at least 3 weeks
after embolization. One patient submitted to a two-stage proce-
dure: a left metastasectomy prior to right PVE. The post-PVE
course was uneventful except for a hepatic hematoma that was
reabsorbed spontaneously in one patient.
FRL was measured by a volumetric helicoidal CT scan before
and 3–4 weeks after embolization. Liver volume was quantified by
landmarks: the middle hepatic vein, gallbladder bed and umbilical
portion of the left portal vein. FRL was computed as a percentage
of total liver volume. FRL hypertrophy was assessed as follows:
(FRL after PVE – FRL before PVE)*100/FRL before PVE. Param-
eters were recorded prospectively, including pre-operative phle-
botomy, as described previously,15 red blood cell and fresh frozen
plasma transfusion. During hospital stay, liver function tests were
conducted, including aspartate aminotransferase, alanine ami-
notransferase, alkaline phosphatase and glutamyltransferase.
Post-surgical complications were defined as a deep venous
thrombosis confirmed by Doppler ultrasound, pulmonary infec-
tion treated with antibiotics, wound infection, biliary leak, hepatic
failure when prothrombin time dropped below 50% and a serum
bilirubin level which peaked over 50 mmol/l on the fifth post-
operative day or thereafter, ascites when abdominal drainage
exceeded 500 ml/day and a pleural effusion which required drain-
age. Duration of hospital stay was recorded. Mortality was mea-
sured until 6 post-operative months. The histological parameters
assessed systematically in 14 patients were: macrovacuolar steato-
sis, classified as the percentage of affected hepatocytes, and vascu-
lar lesions (veno-occlusive), categorized by the degree of severity.
Continuous data were reported as means  SEM. Fisher’s exact
t-test and the Mann–Whitney test were used to compare groups
NC+ and NC-. The data were analyzed using Sigma software
(GraphPad Software, Inc., San Diego, CA, USA). Differences were
considered significant at P < 0.05.
Results
The only obstacle to curative resection was insufficient FRL.
Before PVE, 13 patients (65%) received 6.6 cycles (range 2–18) of
the FOLFIRI-based regimen (5-fluorouracil + leucovorin + irino-
tecan) (NC+) and seven control patients had no chemotherapy
(NC-). NC was mostly given for synchronous metastases (11/13).
FRL increased after PVE, from 29.5  2.6% to 43  2% (P <
0.001) and from 31.1  2% to 43.9  2% (P < 0.001) in the NC+
and NC- groups (Fig. 1), respectively. The FRL hypertrophy rate
was 54.1 7.9% (NC+) and 43.3 6.8% (NC-), respectively (P =
0.38). FRL reached a threshold of resectability in all except one
NC+ patient in whom it rose from 14.8% to 23.5%. Three others
were unresectable because of significant steatosis discovered intra-
operatively in one NC+ patient and tumoral progression after PVE
in two NC- patients with bilobular metastases. Globally, 11/13
NC+ and 5/7 NC- patients underwent hepatectomy (Table 1). NC+
and NC- patients underwent surgery 58 (range 23–127) and 46
(range 22–66) days after PVE, respectively (NS). In NC+ patients,
PVE was performed 14 days (range 1–37) after the end of chemo-
therapy, and liver resection, after 72 days (range 35–140). The
operative parameters were comparable in both groups except for
shorter pedicle clamping duration of 8  3 vs. 36  12 min (P <
0.05) (Table 1). Post-surgical complication rates were comparable:
5/11 (36%) in NC+ and 2/5 (40%) in NC- patients (NS). We
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Figure 1 Future remnant liver (FRL) with or without chemotherapy
after portal vein embolization (PVE)
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pleural effusion requiring drainage in one NC- patient (NS), and
wound infection in one NC- and four NC+ patients (NS). Median
hospital stay for NC+ and NC- patients was 7 and 8 days (P = 0.12),
respectively, without mortality in both groups until 6 months.
Pathology showed macrovacuolar steatosis30% in two patients
from each group (NS) and 30–60% in one NC+ patient who only
received three cycles of the FOLFIRI regimen; in spite of a FRL
hypertrophy rate of 39%, liver resection was cancelled. Also,
liver specimens were slightly cholestatic in two NC- patients and
moderately cholestatic in three NC+ and one NC- patients (NS)
(Table 2).
Discussion
In a large retrospective French study of 1439 CRLM patients, 76%
were initially unresectable; after chemotherapy with a FOLFOX-
based (5-fluorouracil + leucovorin + oxaliplation) regimen, 12.5%
became resectable with 5-year survival and disease-free survival
rates of 33% and 22%, respectively, and a median follow-up of
48.7 months.4 However, NC use increased the lower limit of FRL
after resection from 30% to 40% and induced structural alter-
ations.12,16 After NC, Rubbia-Brandt et al. identified sinusoidal
dilatation in liver specimens with possible parenchyme hemor-
rhage related to rupture of the sinusoidal barrier in 51% persinu-
soidal and 48% veno-occlusive fibrosis.12 Oxaliplatin was a major
risk factor, with 78% of patients developing sinusoidal congestion.
No structural alterations were identified in patients without
chemotherapy. Similar findings were reported by Karoui et al.
with increased morbidity under chemotherapy but no mortality.17
After oxaliplatin-related chemotherapy, vascular lesions appeared
to be the most significant structural alterations.1,12,18
Post-chemotherapy steatosis remains controversial and its
prevalence is fluctuant in the literature, depending on the chemo-
therapy regimen, the duration and interval between the end of NC
and the time of surgery.19 In a cohort study, Kooby et al. discerned
that patients with marked steatosis more likely received NC than
the controls (P < 0.01).20 Also, marked steatosis was sometimes
associated with an increased risk of complications after hepatic
resection but not mortality.19,21,22 Parikh et al. reported mild ste-
atosis (<25%) in 15 and severe steatosis (25%) in 4 out of 34
CRLM patients receiving irinotecan.23 With irinotecan, steatosis
and steatohepatitis seemed to be the predominant lesions.24,25
Caution is advised when using irinotecan-based therapies in ste-
atosic patients (high body mass index, diabetes mellitus, meta-
bolic syndrome) who can develop steatohepatitis with the risk of
progressing to fibrosis and cirrhosis. Assessment of the underlying
liver is critical in the selection of surgical resection type.19 PVE
may provide information about functional hepatic reserves. FRL
hypertrophy after PVE predicts the outcome from hepatectomy.9
If adequate hypertrophy occurs, hepatectomy may be safe. The use
of either a FOLFIRI- or a FOLFOX-based regimen as NC in
CRLM patients is guided by response rates; however, associated
liver injuries, steatohepatitis from the former regimen with the
risk of hepatic failure and veno-occlusion from the latter regimen
without hepatic failure risk, should also be considered. In our
present experience with irinotecan, no significant vascular or ste-
atosic lesions were observed in comparison to NC- patients.
Like other authors,13,26 we conclude that NC did not alter non-
embolized liver hypertrophy. However, Beal et al.27 reported
Table 1 Results of portal vein embolization (PVE) in chemotherapy and control groups
Group NC+ n = 13 Group NC- n = 7
PVE complication 1 liver hematoma 0 NS
FRL hypertrophy rate 54.1  7.9% 43.7  6.8% P = 0.3
FRL at resectability threshold 12/13 7/7





Pedicle clamping duration 8  3 min 36  12 min P < 0.05
Intra-operative bleeding 1031.8  191 ml 1140  290 ml P = 0.7
Red blood cell transfusion 1 unit 1 unit NS
Phlebotomy15 540  84 ml 630  131 ml P = 0.5
Segments retrieved 4.4 (range 4–6) 4 (range 3–5) P = 0.2
FRL, future remnant liver; CRLM, colorectal-liver metastases
aFRL before PVE was 14.78%
Table 2 Histological parameters in chemotherapy and control
groups
NC+ group n = 9 NC- group n = 5
Steatosis
30% 2/9 2/5 NS
>30% 1/9a 0
Sinusoidal alterations
Mild 1 1 NS
Moderate 0 0
Cholestasis
Mild 0 2/5 NS
Moderate 3/9 1/5
aPatient with steatohepatitis in whom liver resection was cancelled
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reduced liver hypertrophy after NC. Caution should be taken in
the interpretation of these data which contained few patients who
received a variety of chemotherapy regimens. Notably, structural
data were not published in their study.13,26,27 Whether structural
alteration-related NC reduces liver hypertrophy after PVE
remains unknown. FRL hypertrophy after PVE varied between
20% and 42%.13,26 Reduced hypertrophy rates have been noted in
diabetic, jaundiced, fibrotic and cirrhotic patients.9,28 However,
Giraudo et al.29 noted that diabetes mellitus, cirrhosis and chemo-
therapy had no effect on the degree of liver hypertrophy, but the
time required to obtain adequate liver hypertrophy was signifi-
cantly longer. We must emphasize that the variety of chemo-
therapy regimens in most series did not affect the degree of liver
growth, but a prospective study is necessary to compare different
chemotherapy regimens with evaluation of histopathological
alterations.
The liver is a quiescent organ, and the hepatocyte replication
rate does not exceed 0.01%.30 After PVE, hepatic cell apoptosis
and atrophy appear on the embolized side, around the periportal
and pericentrolobular areas in association with sinusoidal dilata-
tion which may be a consequence of cellular regression.31 In the
non-embolized side, PVE evokes hepatocyte proliferation for 2
weeks with increased nuclear density and global hepatic mass.31 A
few studies have reported the impact of chemotherapy on liver
proliferation. In rats, 5-fluorouracil suppressed DNA synthesis
and liver cell division when administered within 24 h of hepate-
ctomy but not later.32 In humans, Hewes et al. investigated iso-
lated hepatocytes from liver specimens after CRLM resection.
Prior hepatectomy, oxaliplatin and 5-fluorouracil did not impair
the function or culture integrity of isolated hepatocytes.33 This
observation may be explained by the fact that 5-fluorouracil-
related toxicity is of short duration, and oxaliplatin-related
toxicity is sinusoidal and not hepatocytic. With irinotecan, the
results could be different as steatosis is the predominant toxicity-
related lesion. More investigations should be undertaken includ-
ing irinotecan as well.
Curative resection may be achieved in only 63–75% of CRLM
patients undergoing PVE3,16,29,34 because of the incidental discov-
ery of peritoneal carcinomatosis or CRLM progression. In our
study, planned liver resection was cancelled because of CRLM
progression in two NC- patients. The FRL hypertrophy rate of
structural alteration-related NC livers has to be confirmed in a
large series. NC should be used to control CRLM proliferation, as
it may not deprive patients of FRL hypertrophy after PVE;
however, prospective trials are needed.13,35,36
Summary
Progress in CRLM management is partly as a result of peri-
operative chemotherapy. In our experience and despite a limited
number of patients, we conclude that NC with a FOLFIRI-based
regimen represses tumoral progression and does not alter FRL
hypertrophy after PVE.
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